Paradox Role of Oxidative Stress in Cancer

Contributors: Domenicotti, Cinzia, Marengo, Barbara

Subject Terms: sonodynamic therapy, carbon doped titanium dioxide, sonosensitizers, ultrasound, cancer treatment, breast cancer treatment, radiotherapy, hematological malignancies, oxidative stress, lymphoma, leukemia, multiple myeloma, apoptosis, mitochondria, ultraviolet-C (UVC), withanolide, combined treatment, oral cancer, DNA damage, cancer therapy, immune system, Hypericum perforatum, hyperforin, reactive oxygen species, pH regulation, tumor prevention, tumor therapy, cancerogenesis, inflammatory signaling, natural compounds, pancreatic cancer, antitumor agents, coordination polymers, bioinorganic chemistry, cold atmospheric plasma, reactive oxygen and nitrogen species, nitrite, cancer stem cells, chemoresistance, glutathione, lipid peroxidation, ZEB-1, GPX4, ferroptosis, HO-1, Nrf2, cancer progression, patients, therapy, prognosis, biomarker, Eprenetapopt, Erastin, glutathione (GSH), SLC7A11, iron, NRF2, Medicine and Nursing, Oncology

File Description: application/octet-stream

Access URL: https://directory.doabooks.org/handle/20.500.12854/87477
https://mdpi.com/books/pdfview/book/5665

A thiol‐bound drug reservoir enhances APR‐246‐induced mutant p53 tumor cell death

Authors: Sophia Ceder, Sofi E Eriksson, Emarndeena H Cheteh, Swati Dawar, Mariana Corrales Benitez, Vladimir J N Bykov, Kenji M Fujihara, Mélodie Grandin, Xiaodun Li, Susanne Ramm, Corina Behrenbruch, Kaylene J Simpson, Frédéric Hollande, Lars Abrahmsen, Nicholas J Clemons, Klas G Wiman

Source: EMBO Molecular Medicine, Vol 13, Iss 2, Pp 1-20 (2020)

Subject Terms: APR‐246, Eprenetapopt, glutathione, MRP1, p53, Medicine (General), R5-920, Genetics, QH426-470

File Description: electronic resource

Relation: https://doaj.org/toc/1757-4676; https://doaj.org/toc/1757-4684

Access URL: https://doaj.org/article/ad163b956af24ac198adeee8afcb4f6a

Opportunities for Ferroptosis in Cancer Therapy

Authors: Kenji M. Fujihara, Bonnie Z. Zhang, Nicholas J. Clemons

Source: Antioxidants, Vol 10, Iss 6, p 986 (2021)

Subject Terms: ferroptosis, Eprenetapopt, Erastin, GPX4, glutathione (GSH), SLC7A11, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: https://www.mdpi.com/2076-3921/10/6/986; https://doaj.org/toc/2076-3921

Access URL: https://doaj.org/article/55e6bfc7b61e463cb57689f021384047

Aprea Therapeutics announces acquisition of Atrin Pharmaceuticals Inc and reports 1Q 2022 financial results. [2 tables in original article]

Source: Chemical Business NewsBase (UK), May 16, 2022, 3pp

Aprea Therapeutics reports 2Q 2021 financial results and provides update on business operations. [2 tables in original article]

Source: Chemical Business NewsBase (UK), August 12, 2021, 3pp

Aprea Therapeutics announces clinical hold on lymphoid malignancy programme.

Source: Chemical Business NewsBase (UK), August 12, 2021, 2pp

Aprea Therapeutics announces Phase 1/2 trial of eprenetapopt + venetoclax + azacitidine in TP53 mutant AML meets complete remission primary efficacy endpoint.

Source: Chemical Business NewsBase (UK), June 16, 2021, 2pp

Aprea Therapeutics reports 4Q 2020 and full year 2020 financial results and provides update on business operations. [2 tables in original article]

Source: Chemical Business NewsBase (UK), March 16, 2021, 3pp

Combination Treatment With Eprenetapopt and Azacitidine Shows Promise for TP53-Mutant MDS and AML

Authors: By:Hannah Slater

Source: CancerNetwork (USA), March 2, 2021 News, 3pp

Aprea Therapeutics closes out 2020 with Phase III flop.

Source: Chemical Business NewsBase (UK), December 28, 2020, 2pp

Aprea Therapeutics announces expansion of clinical trial evaluating eprenetapopt for the front-line treatment of TP53 mutant acute myeloid leukaemia (AML).

Source: Chemical Business NewsBase (UK), July 16, 2020, 2pp